Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

BACKGROUND: Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr. OBJECTIVE: To analyze long-term safety with sunitinib in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur Urol
Päätekijät: Porta, Camillo, Gore, Martin E., Rini, Brian I., Escudier, Bernard, Hariharan, Subramanian, Charles, Lorna P., Yang, Liqiang, DeAnnuntis, Liza, Motzer, Robert J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5032140/
https://ncbi.nlm.nih.gov/pubmed/26215605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.07.006
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia